Roth Capital 'Impressed' by Latest Dupixent Data; Affirms Regeneron (REGN) at 'Buy'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Regeneron (REGN): Ready To Go On Approval Of Dupilumab BLA - RBC
October 3, 2016 9:30 AM EDTRBC Capital analyst, Adnan Butt, reiterated his Outperform rating on shares of Regeneron Pharma (NASDAQ: REGN) with the PDUFA expected March 29th. The analyst believes that REGN/SNY will trade up upon approval. The analyst believes expectations are for a strong launch... More
Regeneron (REGN), Sanofi (SNY) Announce Publication of Positive Dupixent Phase 3 Data as AD Treatment
October 3, 2016 6:32 AM EDTRegeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Sanofi (NYSE: SNY) announce that detailed results from LIBERTY AD SOLO 1 and SOLO 2, two placebo-controlled Phase 3 studies evaluating investigational Dupixent (dupilumab) in adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD), were published in the New England Journal of Medicine (NEJM). The studies met their primary endpoints evaluating the extent and severity of the disease. In addition, both trials met key secondary endpoints measuring reduction in itch, improvement in patient-reported anxiety and depression symptoms, and certain quality of life measures.... More
